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Cytokine gene polymorphisms predict acute graft rejection of histocompatibility matching and improved immuno-
following renal transplantation. suppression, the failure of allografts still poses a major
Background. The proinflammatory cytokine tumor necrosis clinical problem [1]. There is evidence that both thefactor-a (TNF-a) has been implicated in the pathogenesis of
frequency and severity of acute rejection episodes (REs)acute rejection, while animal models suggest a role for interleu-
may be a predisposing factor in reduced renal functionkin-10 (IL-10) in promoting graft survival. It has also been
shown that polymorphisms in the TNFA gene promoter (posi- and subsequent graft loss [1–3].
tion 2308) and in the IL-10 gene promoter (position 21082) Acute rejections occur as a result of alloincompatibil-
correlate with differential production of these cytokines in ity between donor and recipient [4], with the humanvitro. The aim of this study was to determine whether TNF-a
leukocyte antigen (HLA) mismatch being a major con-and IL-10 gene polymorphisms influence the incidence and
tributor. This results in CD41 T helper (Th) cell activa-severity of acute rejection in the first six months following renal
transplantation. tion via their initial interaction with the HLA-DR and
Methods. The cytokine genotypes of 115 consecutive first -DQ antigens, which are expressed on donor antigen-
cadaveric kidney allograft recipients and their donors were presenting cells (APC; direct recognition) or with pro-screened. The rejection episodes (REs) were defined clinically
cessed donor antigens presented on recipient APCs byand confirmed histologically where possible and further classi-
the major histocompatibility (MHC) class II antigensfied according to severity (RS), namely steroid-resistant or
responsive REs. The genotypes were then correlated with the (indirect recognition). The effector cells then release
REs and RS. an array of cytokines that promote various mechanisms
Results. The recipient TNF-a high producer genotype and involved in allograft rejection. Cytokines can be catego-IL-10 high producer genotype were significantly associated with
rized into two broad groups [5]. The so-called Th1-typemultiple REs ($2) in human leukocyte antigen (HLA)-DR mis-
cytokines, including interleukin-2 (IL-2), tumor necrosismatched transplants (P 5 0.0047 and P 5 0.045, respectively),
whereas only the TNF-a high producer genotype was associ- factor-a (TNF-a), TNF-b, and interferon-g (IFN-g), me-
ated with steroid-resistant REs (P 5 0.025). When recipient diate cellular immune responses and are proinflamma-
cytokines were analyzed together, the TNF-a high/IL-10 high tory. Second, cytokines described as the Th2 type, whichproducer genotype had the worst prognosis, whereas TNF-a
include IL-4, IL-5, and IL-10, have been shown to inhibitlow/IL-10 low producer genotype was protective.
the development and function of Th1 cells, suppress in-Conclusions. We conclude that recipient TNF-a and IL-10
gene polymorphisms are determinants of REs and RS following flammation, and enhance humoral pathways of the im-
kidney transplantation. Routine screening of these gene poly- mune response.
morphisms may have a clinical role in identifying patients at The proinflammatory cytokine TNF-a, which stimu-risk of multiple REs and severe rejections.
lates macrophage function and increases MHC class II
antigen expression, has been implicated in acute rejec-
Although the one-year survival rate for cadaveric re- tion [6] and chronic rejection [7]. The activation of endo-
nal transplants has increased with greater understanding thelial cells and the subsequent expression of the inter-
cellular adhesion molecule-1 (ICAM-1) induced by
TNF-a can enhance vascular permeability and thereforeKey words: acute rejection, chronic renal dysfunction, graft survival,
cytokines, interleukin-10, kidney transplant. augment the infiltration of proinflammatory granulo-
cytes into the graft [8]. The expression of ICAM-1 onReceived for publication September 17, 1998
the vascular endothelium has been associated with acuteand in revised form December 31, 1998
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[10], and ICAM-1 expression in vitro [11]. Evidence from reduced depending on blood levels. Transplant patients
with delayed graft function were commenced on a tripleanimal transplant models has suggested a role for the
immunoregulatory cytokine IL-10 in promoting graft therapy regimen of CsA, prednisolone, and azathioprine.
Out of the 115 patients considered initially, 15 weresurvival [12]. However, others have provided evidence
supporting the role of IL-10 in rejection [13–15]. subsequently excluded from the study: 4 with allograft
vessel thrombosis or other surgical problems resultingThe level of production of these cytokines at the site
of the allograft could be important in accelerating or in early loss of the graft, 1 because of nonadherence with
the drug regimen, 4 because they lost their grafts tosuppressing rejection. The level of cytokine production
has been associated with polymorphisms in cytokine causes other than rejection in the first three months, and
in 6 because either records were missing or they hadgene promoters [16, 17]. Promoter region polymor-
phisms, it is postulated, may directly or indirectly affect been transferred to other centers for follow-up. Matching
data for the remaining 100 patients showed that 74 outthe binding of transcription factors and might conse-
quently increase or decrease the production of mRNA, of 100, 75 out of 100, and 40 out of 100 had mismatches
at the HLA-A, -B, and -DR loci, respectively. Only 1 ofthus regulating cytokine production. It has been shown
that a G to A polymorphism at position 2308 on the the 40 HLA-DR–mismatched transplants had two mis-
matches. Female recipients made up 29% of all recipi-TNFA gene promoter, giving alleles TNF1 and TNF2,
respectively, is associated with a sixfold to sevenfold ents. Post-transplant patients were followed up regularly
in the transplant clinic, and relevant data were collected.increase in transcription of the TNF-a gene in vitro [18,
19]. Furthermore, it has been demonstrated that this We were able to analyze only 88 corresponding donors
because of the availability of donor DNA samples.polymorphism determines TNF-a production in vitro
[20]. We have previously shown that a G to A polymor-
Control DNA samplesphism (alleles IL-10 1*G and IL-10 1*A, respectively)
at position 21082 in the IL-10 gene promoter correlates Frequencies for TNF-a and IL-10 alleles in nontrans-
plant recipients were determined from laboratory staffwith lower IL-10 production in stimulated lymphocytes
in vitro [17]. and cadaveric kidney transplant donors from a different
cohort.Having established the relationship between cytokine
production and cytokine gene polymorphism, a simple
Rejection episodes and severitypolymerase chain reaction (PCR)-based screening tech-
nique was developed and used to genotype renal trans- Rejection episodes were defined by clinical diagnosis
(elevated serum creatinine in the absence of other pa-plant recipients and their donors. This was performed
to determine the influence of these gene polymorphisms thology, including infection, urinary tract obstruction,
allograft artery stenosis, or CsA toxicity) and were con-on renal allograft REs and severity (RS) in the first six
months following renal transplantation and on chronic firmed by a positive biopsy where possible. All biopsies
were reviewed by a single renal pathologist (I.S.D.R.),transplant nephropathy (CTN) and subsequent graft sur-
vival. Polymorphisms of the TNF-a and IL-10 gene pro- and the Banff 93 working classification criteria were used
in the histological classification of the biopsies [22]. Amoters were analyzed in 115 consecutive first cadaveric
renal patients transplanted between February 1990 and clinically suspected episode of acute rejection was usually
confirmed with a biopsy of the allograft and was treatedJanuary 1991 at our center and who have a minimum
follow-up of five years. with three consecutive intravenous daily doses of 1 g
methylprednisolone and was further classified according
to severity, namely steroid-responsive or steroid-resis-
METHODS
tant acute rejection. Steroid-resistant rejection or a third
Patients and donors episode of rejection was usually treated with anti-thymo-
cyte globulin (ATG). Steroid-responsive acute rejectionsOne hundred and fifteen consecutive recipients of first
cadaveric renal transplants engrafted at a single unit were rejections with creatinine levels returning to within
10% of prerejection levels after a pulse of steroid. Con-between February 1990 and January 1991 were selected
for the study. Recipients were allocated kidneys as pre- versely, REs were considered steroid resistant when cre-
atinine levels remained 10% above that of prerejectionviously described [21]. Selection for transplantation was
based on ABO blood group compatibility, a negative levels after a pulse of steroid and/or required ATG/
OKT3 treatment. Biopsy confirmation of rejection wascomplement-dependent cytotoxicity cross-match using
all historic positive and current sera, and the best HLA obtained in 23 out of 69 (33%) steroid-responsive rejec-
tions and 7 out of 9 (78%) of steroid-resistant rejections.match with no more than three HLA-A, -B and -DR
antigen mismatches. All patients with primary function Similarly, 10 out of 33 (30%) of steroid responsive rejec-
tions and 4 out of 5 (80%) of steroid-resistant rejectionswere given cyclosporine A (CsA) monotherapy at an
initial dose of 15 mg/kg/day. The dosage was gradually were histologically confirmed in patients with HLA-DR–
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mismatched transplants. The RE and the RS values were IL-10 high/low production frequencies between patient
and control groups were analyzed by the Fisher’s exactthen correlated with patients’ cytokine genotypes (high
or low producers). The influence of the cytokine geno- test for 2 3 2 tables (Epi Info 6; CDC, Atlanta, GA,
USA). Results are presented as relative risk (RR), withtype on the REs and the RS was assessed for the first
six-months post-transplant. To study the effect of cyto- 95% confidence intervals (CI). Patients with the high or
low cytokine producer genotypes were further dividedkine gene polymorphism on RS, only the most severe
episode for each individual was used. Patients who died into two groups in terms of REs: those who had less
than 1 or no REs (#1) and those who had multiple REwith functioning grafts or underwent transplant nephrec-
tomy because of nonimmunological complications within ($2). The influence of HLA-A, -B, and -DR matching
and the influence of cytokine genotype on the REs andthis period were therefore excluded from these analyses
(N 5 5). RS were analyzed using the Fisher’s exact test for 2 3
2 tables unless otherwise stated. Similarly, the effect of
Chronic transplant nephropathy cytokine gene polymorphism on CTN and graft survival
was analyzed. A two-tailed P value of less than 0.05 wasChronic transplant nephropathy was defined clinically
as a gradual deterioration of allograft function with a taken to be statistically significant, as well as a P of less
than 0.10 as a trend.mean rise in yearly serum creatinine levels of over 15%
(in the absence of infection, urinary tract obstruction,
allograft artery stenosis, or CsA toxicity). Nine recipients
RESULTS
in this cohort had CTN, of which 6 (66%) were also
Cytokine production genotype frequenciesconfirmed with biopsy.
In the renal transplant group, 80 out of 100 (80%) of
Long-term graft survival patients had the low IL-10 producer genotypes (IL-10
1*G/IL-10 1*A and IL10 1*A/IL-10 1*A) compared withThe effect of the polymorphisms on five-year graft
survival was also assessed. Patients who died with func- 75 out of 119 (63%) of the same genotypes in controls
(P 5 0.08). The TNF-a high producer genotype (TNF2/tioning grafts or who lost their grafts because of nonim-
munological reasons were excluded from this analysis. TNF2, TNF2/TNF1) and the TNF-a low producer geno-
type (TNF1/TNF1) frequencies were similar in both
DNA extraction groups. We also assessed the influence of cytokine gene
polymorphisms on original disease but found no signifi-Genomic DNA from whole blood or frozen cells was
obtained by phenol extraction and ethanol precipitation cant association, perhaps because of the low numbers in
each category.following proteinase K (Boehringer Mannheim, Mann-
heim, Germany) digestion.
Effect of human leukocyte antigen-A, -B, and -DR
mismatch on rejection episodesCytokine promoter region polymorphism analysis
The TNFA promoter polymorphism at position 2308 Mismatches in both HLA-A, -B, and -DR did not
influence REs and RS in the first six-months post-trans-was analyzed by PCR-restriction fragment length poly-
morphism (PCR-RFLP) as previously described (ab- plant. However, there was a significantly greater propor-
tion of recipients with HLA-DR–mismatched trans-stract; Wilson et al, Human Mol Genet 1:353, 1992).
Individuals with the rarer allele TNF2 (including both plants with multiple REs as compared with those with
zero mismatches when only early REs up to three-homozygotes and heterozygotes) were considered TNF-a
high producers. IL-10 promoter gene polymorphism was months post-transplantation were considered (12 out of
40 with HLA-DR–mismatched transplants had multipleanalyzed using sequence-specific oligonucleotide probes
(SSOP) as previously described by Turner et al [17]. The RE as compared with only 7 out of 60 with matched
transplants, P 5 0.042, Yates analysis).biotinylated oligonucleotide probes were designed to de-
tect polymorphism in a dot blot technique. Individuals
Cytokine gene polymorphisms and rejection episodeswho were IL-10 1*A positive (including both homozy-
gotes and heterozygotes) were classified as IL-10 low Recipients and donors were grouped into high or low
cytokine producer genotypes, and these data were corre-producers according to previously defined criteria [17].
The technical aspects of genotyping have been described lated with REs (Table 1). When all patients were ana-
lyzed independently of HLA-DR matching, no associa-in detail [23].
tion was found between cytokine gene polymorphism
Statistical analysis and REs. However, the recipient TNF-a high producer
genotype (TNF2 positive) showed an association withPatients were grouped into the predicted high or low
producer phenotypes according to their genotypes as increased REs only when the HLA-DR–mismatched
transplants were analyzed separately. A greater propor-defined previously [16, 17, 23]. Differences in TNF-a and
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Table 1. Association between recipient and donor cytokine genotype and frequency of rejection episodes (RE)
in the first six months following renal transplantation
Number of individuals and RE
All transplants HLA-DR mismatched transplants
Predicted
Genotye phenotype #1 RE $2 RE P #1 RE $2 RE P
Recipient TNF-a TNF2 positive high 24 12 NS 3 7 0.0047
TNF2 negative low 50 9 23 5
Recipient IL-10 IL-10 1*A negative high 11 7 NS 4 6 0.045
IL-10 1*A positive low 63 14 22 6
Donor TNF-a TNF2 positive high 24 11 NS 9 6 NS
TNF2 negative low 39 9 14 6
Donor IL-10 IL-10 1*A positive high 23 6 NS 3 3 NS
IL-10 1* negative low 40 14 20 9
tion of the recipients with TNF-a high producer genotype genotypes (10 out of 17, 59%, P 5 0.003, RR 5 0.16,
95% CI, 0.04 to 0.64, Yates analysis). However, no asso-had multiple REs (7 out of 10, 70%) compared with
recipients with the TNF-a low producer (TNF2 negative) ciations were found with the presence or absence of
REs and the recipient TNF-a high/IL-10 high producergenotype (5 out of 28, 18%, P 5 0.0047, RR 5 3.92,
genotype (TNF2 positive/IL-10 1*A negative).95% CI, 1.61 to 9.57). Similarly, a greater proportion of
recipients with IL-10 high producer genotype (IL-10 1*A
Cytokine gene polymorphism and rejection severitynegative) had multiple REs (6 out of 10, 60%) as com-
When the effect of cytokine gene polymorphisms onpared with only 6 out of 28 (21%) recipients with the
RS was analyzed, only the recipient TNF-a high pro-IL-10 low producer genotype (IL-10 1*A positive; P 5
ducer genotype (TNF2 positive) was associated with in-0.045, RR 5 2.80, 95% CI, 1.17 to 6.69). Furthermore,
creased RS (Table 3). Seven out of 21 (33%) recipientswhen the recipients were classified according to the pres-
with the TNF-a high producer genotype had steroid-ence or absence of REs, the recipient TNF-a high pro-
resistant rejections compared with 2 out of 29 (7%) recip-ducer genotype, but not the IL-10 high producer geno-
ients with the TNF-a low producer genotype (TNF2 neg-type, was associated with an increase in the incidence of
ative, P 5 0.025, RR 5 4.83, 95% CI, 1.11 to 20.97).REs in HLA-DR–mismatched transplants. Nine out of
Five out of the seven steroid-resistant rejections in the10 (90%) of the recipients with the TNF-a high producer
recipients with the TNF-a high producer genotype weregenotype (TNF2 positive) had one or more REs com-
biopsy confirmed rejections: one was Banff grade 4 (III),pared with 13 out of 28 (46%) of recipients with the
two were grade 4 (IIb), and the remaining two wereTNF-a low producer genotype (TNF2 negative, P 5
grade 4 (IIa) and 4 (I) rejections. Although the IL-100.06). No associations with multiple REs were found
high producer genotype (IL-10 1*A negative) was notwhen donor TNF-a and IL-10 genotypes were analyzed
significantly correlated to steroid-resistant rejections,(Table 1).
there was a positive trend linking the IL-10 high producer
Cytokine gene polymorphism profile and genotype to steroid-resistant rejections (P 5 0.065, RR 5
rejection episodes 3.20, 95% CI, 1.05 to 9.78). Out of the four steroid-
resistant rejections in the IL-10 high producer group,To assess the combined effect of cytokine polymor-
only two had biopsy confirmation, and both were gradedphism combinations in relation to REs, we analyzed data
4 (I). No associations with RS were found when donorfor both TNF-a and IL-10 together for individual recipi-
TNF-a and IL-10 genotypes were analyzed (Table 3).ents. Only HLA-DR–mismatched transplants were ana-
lyzed because we have shown that only mismatching at
Cytokine gene polymorphism profile andthis locus increases REs in recipients with TNF-a and
rejection severityIL-10 in this cohort (Table 1). A greater proportion
of recipients with the TNF-a high/IL-10 high producer To assess the combined effect of cytokine gene poly-
morphism in relation to RS, we analyzed data for bothgenotype (TNF2 positive/IL-10 1*A negative) had multi-
ple REs (3 out of 3, 100%) as compared with 9 out of TNF-a and IL-10 together for individual patients (Table
4). A greater proportion of recipients with the TNF-a35 (26%) with all other genotypes (P 5 0.026, RR 5 3.89;
95% CI, 2.21 to 6.83; Table 2). Conversely, significantly high/IL-10 high producer genotype (TNF2 positive/
IL-10 1*A negative) had steroid-resistant rejections (3fewer patients with the TNF-a low/IL-10 low producer
genotype (TNF2 negative/IL-10 1*A positive) had multi- out of 4, 75%) as compared to 6 out of 46 (13%) of
those with all other genotypes (P 5 0.015, RR 5 5.75,ple REs (2 out of 21, 10%) as compared with all other
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Table 2. Association between recipient tumor necrosis factor-a (TNF-a) and interleukin-10 (IL-10) genotype profile and rejection episodes
(RE) in the first six months following renal transplantation in HLA-DR mismatched transplants
Number of patients and cytokine producer genotype
TNF2 positive TNF2 positive TNF2 negative TNF2 negative
Cytokine genotype Il-10 1*A negative IL-10 1*A positive IL-10 1*A negative IL-10 1*A positive
TNF-a high TNF-a high TNF-a low TNF-a low
Predicted phenotype IL-10 high IL-10 low IL-10 high IL-10 low
#1 RE 0 3 4 19
$2 RE 3a 4 3 2b
a Significantly more patients with the TNF-a high/IL-10 high producer genotype had muliple RE (3/3, 100%) as compared to 9/35 (26%) with all other genotypes
(P 5 0.026, RR 5 3.89, 95% CI 2.21–6.83)
b Significantly fewer patients with the TNF-a low/IL-10 low producer genotype had multiple RE (2/21, 8%) as compared to 10/17 (59%) with all other genotypes,
(P , 0.003, RR 5 0.16, 95% CI 0.04–0.064)




Cytokine genotype phenotype responsive RE resistant RE P
Recipient TNF-a TNF2 positive high 14 7 0.025
TNF2 negative low 27 2
Recipient IL-10 IL-10 1*A negative high 6 4 0.065
IL-10 1*A positive low 35 5
Donor TNF-a TNF2 positive high 13 5 NS
TNF2 negative low 23 4
Donor IL-10 IL-10 1*A negative high 11 3 NS
IL-10 1*A positive low 25 6
Table 4. Association between recipient TNF-a and IL-10 genotype profile and RS in the first six months following
renal transplantation in HLA-DR mismatched transplants
Number of patients and cytokine producer genotype
TNF2 positive TNF2 positive TNF2 negative TNF2 negative
Cytokine genotype Il-10 1*A negative IL-10 1*A positive IL-10 1*A negative IL-10 1*A positive
TNF-a high TNF-a high TNF-a low TNF-a low
Predicted phenotype IL-10 high IL-10 low IL-10 high IL-10 low
Steroid responsive RE 1 13 5 22
Steroid resistant RE 3a 4 1 1b
a Significantly more recipients with the TNF-a high/IL-10 high producer genotype had steroid resistant RE (3/4, 75%) as compared to 6/46 (13%) of those with
all other genotypes (P 5 0.015, RR 5 5.75, 95% CI 2.25–14.67)
b Significantly fewer recipients with the TNF-a low/IL-10 low producer genotype had steroid resistant RE (1/23, 4%) as compared to 8/27 (30%) of those with all
other genotypes, (P , 0.028, RR 5 0.15, 95% CI 0.02–1.09)
95% CI, 2.25 to 14.67). Only one third of the steroid- correlation between TNF-a and IL-10 genotypes, with
resistant rejections in the recipients with the TNF-a high/ CTN and the subsequent survival of graft at five-years
IL-10 high producer genotype were biopsy proven and post-transplant.
were graded as Banff grade 4 (I). Conversely, signifi-
cantly fewer patients with the TNF-a low/IL-10 low pro-
DISCUSSIONducer genotype (TNF1 negative/IL-10 1*A positive) had
Cytokines have been implicated in the regulation ofsteroid-resistant rejections (1 out of 23, 4%) as compared
acute rejection. In this study, we investigated the role ofwith all other genotypes (8 out of 27, 30%, P 5 0.028,
recipient and donor cytokine gene polymorphism onRR 5 0.15, 95% CI, 0.02 to 1.09).
REs and RS. These gene polymorphisms have been
Effect of cytokine genotype on chronic transplant shown to influence interindividual production of the re-
nephropathy and long-term graft survival spective cytokines in vitro. The interindividual differ-
ences in cytokine production have the potential to influ-At five-years post-transplant, 9 out of 100 patients had
lost their grafts through chronic rejection. There was no ence the various immune and inflammatory responses
Sankaran et al: Cytokine genotype and acute rejection286
within the graft. This difference in cytokine production release in patients with the TNF2-positive genotype who
also received a HLA-DR–mismatched transplant. Fur-between individuals is expected to be exacerbated in the
presence of HLA-A, -B, or -DR mismatching. Although thermore, the recipient TNF-a high producer genotype
was associated with steroid-resistant REs (Table 3).this study could not demonstrate that HLA-A, -B, and
-DR matched transplants had significantly fewer REs or When the high IL-10 production genotype was ana-
lyzed in all the patients, it was not associated with REs.less severe rejections in the first six months following
transplantation, we observed a trend indicating a protec- However, in recipients with HLA-DR–mismatched
transplants, the IL-10 high producer genotype was asso-tive effect of HLA-DR matching in REs in the first three
months following renal transplantation compared with ciated with an increase in the incidence of multiple REs
(Table 1). This association was weaker than that ofmismatched transplants. This is not unusual and supports
other studies with similar observations [24]. The CD41 TNF-a. This correlation was surprising considering the
anti-inflammatory functions of IL-10. We had expectedTh cells are activated directly via donor alloantigens
associated with the HLA molecules expressed on the that the high IL-10 production would act against the
production of the proinflammatory Th1-type cytokinesgraft. Therefore, matching at the HLA-DR locus would
reduce Th-cell activation and alloantigen recognition. such as TNF-a and hence suppress acute graft rejection.
However, recent reports have suggested that IL-10 mayThe smaller number of REs might be attributed to the
down-regulation of Th-cell effector functions and cyto- enhance antibody responses against the graft [13] and
low IL-10 responses can be used to predict a low riskkine release.
The analysis of the high/low cytokine producer geno- for acute graft rejection [14]. Furthermore, IL-10 is a
potent stimulator, inducing differentiation and prolifera-type frequencies showed that the frequency of the IL-10
low producer genotype in renal recipients was higher tion of B cells, thus driving the immune response toward
the humoral pathway [27].when compared with normal controls. Even though this
difference was only approaching statistical significance, Previously, our laboratory has documented in heart
transplant recipients that a certain combination ofit may suggest that the IL-10 high producer genotype
could have a protective effect against certain of the origi- TNF-a and IL-10 gene polymorphisms (the TNF-a high/
IL-10 low group) was associated with higher levels ofnal diseases progressing to end-stage renal failure. This
finding fits in well with the observation that in vitro rejection [28]. This underlines the complex nature of allo-
graft rejection and emphasizes the importance of study-pretransplant B-cell responses in patients with end-stage
renal disease were significantly lower compared with ing the role of a cytokine in the context of others. There-
fore, to determine the combined effect of TNF-a andhealthy controls [14] because IL-10 is essential for B-cell
growth and development. IL-10 genotypes on REs and RS in renal transplant pa-
tients, we categorized the patients into the four possibleWhen recipient TNF-a gene polymorphisms were ana-
lyzed individually in all recipients, we did not find any genotype combinations and correlated these with the
REs (Tables 2 and 4). We found the TNF-a high/IL-10relationship between the genotypes and the incidence of
multiple REs (Table 1). This result could be explained by high producer genotype to give a strong association with
the incidence of multiple REs in HLA-DR–mismatchedthe effect of high-dose CsA immunosuppressive therapy
during the early post-transplant period. The action of transplants and with steroid-resistant REs. Contrary to
previous studies, which indicated a protective role ofCsA in inhibiting the production and release of the proin-
flammatory Th1 cytokines is well documented [25]. The IL-10 in transplant rejection [12, 29], we found that the
IL-10 high producer genotype did not protect againsttranscription of the TNF-a gene, which requires the
translocation of the cytoplasmic nuclear factor of activa- the influence of the TNF-a high producer genotype. A
recipient TNF-a high/IL-10 high producer genotype maytion of T cells, may be inhibited by CsA [25]. Alterna-
tively, the effect of the TNF-a high producer genotype influence REs by the up-regulation of both the cellular
and humoral responses. Why this genotype combinationmight have been masked when we analyzed all of the
patients together independently of HLA-DR matching is associated with rejection in kidney but not in heart
transplants is uncertain. One reason may be because ofstatus. This explanation is more plausible because 60%
of our transplants were matched at the HLA-DR locus. an organ to organ variation that may affect the microen-
vironment in which the cytokines exert their influence.Furthermore, in patients with highly allogeneic HLA-
DR–mismatched transplants, the TNF-a high producer Another reason may be the use of a different immuno-
suppressive regimen for patients receiving heart trans-genotype was linked with the presence of REs and was
strongly associated with an increase in the incidence of plants (triple therapy of CsA, prednisolone, and azathio-
prine). We also note that when patients with delayedmultiple REs (Table 1). This may be attributed to the
fact that CsA does not totally block cytokine production graft function were analyzed separately, two out of five
(40%) with the TNF-a high/IL-10 low producer geno-[26]. From our results, we suggest that CsA monotherapy
post-transplant may be insufficient for blocking TNF-a type had multiple REs compared with 0 out of 16 (0%)
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